Tilak Healthcare's core product is OdySight, a CE‑marked Class I medical device that combines a mobile video game with remote monitoring to track visual acuity for retinal diseases such as AMD and diabetic retinopathy. OdySight is financed by the French social security system under the government’s ‘Article 51’ scheme for experimental technologies and is already used in Europe and the United States. Since launch it has improved care for about 12,000 patients and is distributed in part via a co-promotion partnership with Laboratoires Théa. The company says its telemedicine model has created a sustainable business model and is on the path to achieve profitability by 2025. Tilak reported a 500% increase in recurring revenue between 2022 and 2023. The company was founded in 2016 within the iBionext ecosystem and has raised €22 million in total funding to date. Tilak Healthcare develops OdySight, a CE‑labelled Class I medical game for mobile devices that remotely monitors visual acuity in patients with retinal diseases such as age‑related macular degeneration and diabetic retinopathy. The app has been used to optimize care pathways for thousands of patients across Europe and the USA and is used by nearly 20% of retinologists in France. The company combines video‑game developers and medical scientists under guidance from Professor José‑Alain Sahel and is led by CEO Edouard Gasser. Products are clinically validated, compliant with medical device regulations, and built to protect patient privacy. Tilak is expanding internationally (USA, Spain, Belgium) and plans to launch OdySight Care for clinical trials and health‑insurance preventative monitoring. Financially, the company has completed a new fundraising round and has raised over €12 million since its 2016 founding. Tilak Healthcare develops medically-prescribed video games for the diagnosis and follow-up of chronic diseases. Cofounded with iBionext in May 2016 and led by CEO Edouard Gasser, the company is specialized in digital healthcare. It is dedicated to creating disruptive videogames that can be prescribed to monitor and follow up patients. The company's first application targets ophthalmology, with a focus on macular diseases that affect many patients in aging populations of developed countries. Tilak intends to use new funding to accelerate the development of its therapeutic mobile games. The company raised €2.5m from iBionext Growth Fund.

Total raised

$21M

Funding rounds

3

Latest round

Equity

Latest activity

Oct 2023